secwatch.observer — SEC 8-K summary
======================================

Issuer:     First Tracks Biotherapeutics, Inc. (TRAX)
CIK:        0002091349
Form:       8-K
Filed at:   2026-05-14T20:24:52+00:00
Accession:  0001193125-26-224124
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

First Tracks Q1 net loss $50.5M; launched with $180M cash; ANB033 Phase 1b data expected Q4 2026
--------------------------------------------------------------------------------

- Net loss of $50.5M for Q1 2026 vs $47.2M in Q1 2025; R&D expense $34.0M (down from $41.5M).
- Launched on April 20 with $180M cash and a two-year runway to fund ANB033 and other programs.
- ANB033 Phase 1b trials in celiac disease and eosinophilic esophagitis ongoing; top-line data Q4 2026 and mid-2027.
- Rosnilimab had productive End-of-Phase 2 FDA meeting for RA; company assessing strategic options.
- G&A expense rose to $18.9M from $9.8M due to separation costs and stock compensation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2091349/000119312526224124/0001193125-26-224124-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2091349/000119312526224124/trax-20260514.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-224124

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer